hydroxyurea has been researched along with Airflow Obstruction, Chronic in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "While oral zileuton during COPD exacerbations that require hospital admission is safe and reduces urinary LTE(4) levels, we found no evidence suggesting that this intervention shortened hospital stay, with the limitation that our sample size may have been insufficient to detect a modest but potentially meaningful clinical improvement." | 2.76 | Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. ( Albert, RK; Bailey, WC; Casaburi, R; Connett, JE; Cooper, JA; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Harnden, SM; Kim, V; Lazarus, SC; Marchetti, N; Martinez, FJ; McEvoy, CE; Niewoehner, DE; Reilly, JJ; Rice, K; Scanlon, PD; Scharf, SM; Sciurba, FC; Washko, GR; Woodruff, PG, 2011) |
| " dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications." | 2.44 | Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. ( Berger, W; Cairns, CB; De Chandt, MT, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schoenfeld, J | 1 |
| Tulbert, BH | 1 |
| Cusack, CA | 1 |
| Woodruff, PG | 1 |
| Albert, RK | 1 |
| Bailey, WC | 1 |
| Casaburi, R | 1 |
| Connett, JE | 1 |
| Cooper, JA | 1 |
| Criner, GJ | 1 |
| Curtis, JL | 1 |
| Dransfield, MT | 1 |
| Han, MK | 1 |
| Harnden, SM | 1 |
| Kim, V | 1 |
| Marchetti, N | 1 |
| Martinez, FJ | 1 |
| McEvoy, CE | 1 |
| Niewoehner, DE | 1 |
| Reilly, JJ | 1 |
| Rice, K | 1 |
| Scanlon, PD | 1 |
| Scharf, SM | 1 |
| Sciurba, FC | 1 |
| Washko, GR | 1 |
| Lazarus, SC | 1 |
| Berger, W | 1 |
| De Chandt, MT | 1 |
| Cairns, CB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antileukotriene Therapy for COPD Exacerbations[NCT00493974] | Phase 3 | 119 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of feasibility due to low recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in Post-bronchodilator FEV1/FEV6 ratio comparing data at discharge visit with baseline. (NCT00493974)
Timeframe: from baseline to day of discharge
| Intervention | ratio (Mean) |
|---|---|
| Zileuton | 0.02 |
| Placebo | 0.03 |
Change in Post-bronchodilator FEV1% predicted comparing data at 30 day visit with baseline. (NCT00493974)
Timeframe: Measured at Baseline and Day 30
| Intervention | percent predicted (Mean) |
|---|---|
| Zileuton | 6.8 |
| Placebo | 8.0 |
Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 24 Hours (NCT00493974)
Timeframe: Baseline and 24 hours
| Intervention | (ng/mg Cr.) (Log Mean) |
|---|---|
| Zileuton | -1.38 |
| Placebo | 0.14 |
Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 72 Hours (NCT00493974)
Timeframe: Baseline and 72 hours later
| Intervention | (ng/mg Cr.) (Log Mean) |
|---|---|
| Zileuton | -1.32 |
| Placebo | 0.26 |
"St. George's Respiratory Questionnaire - Total Score~The SGRQ was asked with respect to the last one month as validated for acute exacerbations of COPD by Doll et al.~Scale from 0 (no disability) to 100 (maximum disability).~The SGRQ total score summarizes the impact of airway specific disease on overall health status. Scores range from zero (no impairment) to 100 (maximum impairment). Scores were calculated using the SGRQ scoring Algorithm." (NCT00493974)
Timeframe: Change from Baseline and 1 Month
| Intervention | Units on a scale (Mean) |
|---|---|
| Zileuton | -10.6 |
| Placebo | -8.5 |
Admission will begin at the time the subject has been admitted to an inpatient service. Length of Stay (LOS) will be recorded in days. The LOS will be based on the number of days spent in an acute medical ward or in the ICU. Subjects that are admitted and discharged in the same 24 hour period will be recorded as a LOS of 1 day, as will subjects discharged in the ensuing 24 hour period. LOS's greater than 10 days will be truncated to 10 days. (NCT00493974)
Timeframe: Measured at Day 30
| Intervention | Days (Median) |
|---|---|
| Zileuton | 3 |
| Placebo | 3 |
Treatment failure is defined as death, intubation, readmission to a hospital for COPD, urgent visit to an outpatient or ED provider for symptoms of COPD or intensification of therapy [including second course of antibiotics for COPD, and second course of systemic steroids for COPD]) in the first 30 days after randomization. (NCT00493974)
Timeframe: Baseline to day 30 visit
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Death | Intubation | Hospital Readmission | Urgent Visit | Intensification of therapy | Any Treatment Failure | |
| Placebo | 2 | 1 | 7 | 6 | 11 | 16 |
| Zileuton | 1 | 1 | 7 | 7 | 11 | 14 |
1 review available for hydroxyurea and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dermatitis, Atopic; Drug Administration Schedule; H | 2007 |
1 trial available for hydroxyurea and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
Topics: Aged; Biomarkers; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans | 2011 |
1 other study available for hydroxyurea and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Transverse melanonychia and palmar hyperpigmentation secondary to hydroxyurea therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; Female; Hand; Humans; Hydroxyurea | 2017 |